Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...

Welcome to Knox Pages’ 2024-25 high school basketball preview. This season, we’re diving deep into all the local varsity basketball action. Over the coming days, we’ll highlight both boys’ and […] ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

While oral PrEP is effective in curbing the risk of HIV infection, it needs to be followed consistently every day for ...

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to ...

Considering “health equity aspects”, Moupali Das highlighted the historic underrepresentation of disproportionately affected ...